NCNA NuCana plc IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1709626 · Reporting currency GBP · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: GBP | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | 12.74M | 18.02M |
| Operating income | -20.11M | -22.81M |
| Interest expense | 12.65M | 0 |
| Pretax income | -30.52M | -22.45M |
| Income tax | -1.17M | -3.45M |
| Net income | -29.35M | -19.00M |
| EBITDA | -19.84M | -22.29M |
| EPS (basic) | 0.00 | -0.26 |
| EPS (diluted) | 0.00 | -0.26 |
| Balance sheet | ||
| Cash & equivalents | 24.25M | 6.75M |
| Receivables | 849,000 | 922,000 |
| Current assets | 26.86M | 12.27M |
| PP&E, netmay include right-of-use assets (IFRS) | 658,000 | 197,000 |
| Intangibles | 2.20M | 2.20M |
| Total assets | 29.83M | 14.77M |
| Current liabilities | 4.79M | 8.67M |
| Total liabilities | 5.51M | 8.82M |
| Shareholders' equity | 24.33M | 5.95M |
| Cash flow statement | ||
| Operating cash flow | -7.47M | -19.12M |
| Capital expenditure | 0 | 4,000 |
| Free cash flow | -7.47M | -19.12M |
| Investing cash flow | 159,000 | 79,000 |
| Financing cash flow | 25.01M | 8.18M |
| Depreciation & amortization | 274,000 | 522,000 |
| Stock-based compensation | 10.03M | 1.65M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, GBP, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.